Gennady Belitsky1, Timur Fetisov1, Kirill Kirsanov1,2, Ekaterina Lesovaya1,3, Olga Vlasova1, Marianna Yakubovskaya1. 1. Department of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia. 2. Faculty of Basic Therapy, Peoples' Friendship University of Russia Moscow 117198, Russia. 3. Division of Oncology, Pavlov Ryazan State Medical University Ryazan 390026, Russia.
Abstract
BACKGROUND: Secondary tumors, including therapy-related acute myeloid leukemia (t-AML), represent one of the most undesirable side effects of chemotherapy, which arise several years after primary cancer treatment. This review aims to analyze the current data on molecular pathogenesis of t-AML revealing potential criteria for predicting predisposition to the disease. Another objective is to analyze the information on promising approaches for t-AML prevention. METHODS: We analyzed studies regarding t-AML and possible approaches for cancer prevention of drug-induced tumors. Publications in the databases, such as SciVerse Scopus (948), PubMed (1837) and Web of Science (935) were used. Among 92 the most important publications cited in the review, 79 were published during the last decade. RESULTS: The review provides the information concerning t-AML pathogenesis, molecular markers of primary cancer patients with high risk of t-AML. The role of the bone marrow niche in clonal hematopoiesis and t-AML pathogenesis is discussed. Current approaches for t-AML prevention both at the stage of therapy and at the latent period are described. Inhibition effects of polyphenols on cell proliferation and on the appearance of hemopoetic clones of indeterminate potential are proposed for t-AML prevention. CONCLUSION: The problem of the t-AML, a cancer induced by genotoxic chemotherapeutic drugs, is considered from the point of view of the fundamental mechanisms of chemical carcinogenesis, highlighting initiation and promotion stages. It enables to reveal the possible markers for the group of patients with high risk for t-AML and to demonstrate perspectives for the use of plant polyphenols for t-AML prevention. AJBR
BACKGROUND: Secondary tumors, including therapy-related acute myeloid leukemia (t-AML), represent one of the most undesirable side effects of chemotherapy, which arise several years after primary cancer treatment. This review aims to analyze the current data on molecular pathogenesis of t-AML revealing potential criteria for predicting predisposition to the disease. Another objective is to analyze the information on promising approaches for t-AML prevention. METHODS: We analyzed studies regarding t-AML and possible approaches for cancer prevention of drug-induced tumors. Publications in the databases, such as SciVerse Scopus (948), PubMed (1837) and Web of Science (935) were used. Among 92 the most important publications cited in the review, 79 were published during the last decade. RESULTS: The review provides the information concerning t-AML pathogenesis, molecular markers of primary cancerpatients with high risk of t-AML. The role of the bone marrow niche in clonal hematopoiesis and t-AML pathogenesis is discussed. Current approaches for t-AML prevention both at the stage of therapy and at the latent period are described. Inhibition effects of polyphenols on cell proliferation and on the appearance of hemopoetic clones of indeterminate potential are proposed for t-AML prevention. CONCLUSION: The problem of the t-AML, a cancer induced by genotoxic chemotherapeutic drugs, is considered from the point of view of the fundamental mechanisms of chemical carcinogenesis, highlighting initiation and promotion stages. It enables to reveal the possible markers for the group of patients with high risk for t-AML and to demonstrate perspectives for the use of plant polyphenols for t-AML prevention. AJBR
Authors: Lois B Travis; Sophie D Fosså; Sara J Schonfeld; Mary L McMaster; Charles F Lynch; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Eero Pukkala; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Timo Joensuu; Randi J Cohen; John D Boice; Graça M Dores; Ethel S Gilbert Journal: J Natl Cancer Inst Date: 2005-09-21 Impact factor: 13.506
Authors: Tibor J Kovacsovics; Alice Mims; Mohamed E Salama; Jeremy Pantin; Narayanam Rao; Ken M Kosak; Peter Ahorukomeye; Martha J Glenn; Michael W N Deininger; Kenneth M Boucher; Linda M Bavisotto; Gerardo Gutierrez-Sanchez; Thomas P Kennedy; Stephen G Marcus; Paul J Shami Journal: Blood Adv Date: 2018-02-27
Authors: Christopher R Cogle; Raphael C Bosse; Takae Brewer; Yazan Migdady; Reza Shirzad; Kim Rosalie Kampen; Najmaldin Saki Journal: Cancer Lett Date: 2015-05-08 Impact factor: 8.679
Authors: Peter Valent; Wolfgang Kern; Gregor Hoermann; Jelena D Milosevic Feenstra; Karl Sotlar; Michael Pfeilstöcker; Ulrich Germing; Wolfgang R Sperr; Andreas Reiter; Dominik Wolf; Michel Arock; Torsten Haferlach; Hans-Peter Horny Journal: Int J Mol Sci Date: 2019-02-12 Impact factor: 5.923
Authors: Katherine E Reeder-Hayes; Anne Marie Meyer; Sharon Peacock Hinton; Ke Meng; Lisa A Carey; Stacie B Dusetzina Journal: J Clin Oncol Date: 2017-07-20 Impact factor: 50.717